Biomarkers to predict risk of venous thromboembolism in patients with rheumatoid arthritis receiving tofacitinib or tumour necrosis factor inhibitors

By sjmartinez • November 3, 2022

Weitz JI, Szekanecz Z, Charles-Schoeman C, Vranic I, Sahin B, Paciga SA, Wang Z, Hyde C, Martin DA. Biomarkers to predict risk of venous thromboembolism in patients with rheumatoid arthritis receiving tofacitinib or tumour necrosis factor inhibitors. RMD Open. 2022 Nov;8(2):e002571. doi: 10.1136/rmdopen-2022-002571. PMID: 36323490.

Tags: Antirheumatic Agents, Arthritis, cardiovascular diseases, Publications, Rheumatoid, Rheumatology

Clinical Outcomes and Health Care Costs in Patients Hospitalized With Heart Failure and Transthyretin Amyloid Cardiomyopathy: Findings From GWTG-HF

Shoji S, Ikeaba U, Fonarow GC, Selvaraj S, Lewsey SC, Pandey A, Khouri MG, Alhanti B, McDermott JJ, Wright J, Vaduganathan M, Greene SJ. Clinical[...]

A practical approach to Cardiopulmonary Exercise Testing: from functional evaluation to adapted exercise prescription

Neunhaeuserer D, Gevaert AB, Hansen D, Battista F, Bauer P, Davos CH, Ermolao A, Sanz-de la Garza M, Guazzi M, Howden EJ, Laukkanen J, Mueller-Stegner[...]

Gut microbe-generated metabolite trimethylamine N-oxide and risk of abdominal aortic aneurysm: a cohort study

Li XS, Wang M, Wang Z, Fan B, Tian MY, Filippazzo J, Lee Y, Mallela DP, Mao K, Liu Y, Lemaitre RN, Xie V, Diaz[...]